Nti, Akosua A <br/><br/>
FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.  [electronic resource] 

 -  Retina (Philadelphia, Pa.)  Mar 2019 
 - 502-513 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1539-2864 
<br/><br/><label>Standard No.: </label>10.1097/IAE.0000000000002027  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--adverse effects<br/>Enzyme Inhibitors--adverse effects<br/>Female<br/>Humans<br/>Hydroxychloroquine--adverse effects<br/>Imidazoles--adverse effects<br/>MAP Kinase Kinase 1--antagonists & inhibitors<br/>Macula Lutea--pathology<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Oximes--adverse effects<br/>Photoreceptor Cells--pathology<br/>Protein Kinase Inhibitors--adverse effects<br/>Proto-Oncogene Proteins B-raf--antagonists & inhibitors<br/>Pyridones--adverse effects<br/>Pyrimidinones--adverse effects<br/>Retinal Diseases--chemically induced<br/>Retinal Pigment Epithelium--pathology